Meryl Brod

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2712453/publications.pdf

Version: 2024-02-01

		257450	138484
68	3,593	24	58
papers	citations	h-index	g-index
69	69	69	4745
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2004, 2, 12.	2.4	722
2	Qualitative research and content validity: developing best practices based on science and experience. Quality of Life Research, 2009, 18, 1263-1278.	3.1	617
3	The Impact of Non-Severe Hypoglycemic Events on Work Productivity and Diabetes Management. Value in Health, 2011, 14, 665-671.	0.3	240
4	Psychological insulin resistance: patient beliefs and implications for diabetes management. Quality of Life Research, 2009, 18, 23-32.	3.1	174
5	Validation of the Adult Attention-Deficit/Hyperactivity Disorder Quality-of-Life Scale (AAQoL): A Disease-Specific Quality-of-Life Measure. Quality of Life Research, 2006, 15, 117-129.	3.1	148
6	Content validity of patient-reported outcome measures: perspectives from a PROMIS meeting. Quality of Life Research, 2012, 21, 739-746.	3.1	143
7	ADHD burden of illness in older adults: a life course perspective. Quality of Life Research, 2012, 21, 795-799.	3.1	104
8	Development and validation of the insulin treatment satisfaction questionnaire. Clinical Therapeutics, 2004, 26, 565-578.	2.5	103
9	Impact of nocturnal hypoglycemic events on diabetes management, sleep quality, and next-day function: results from a four-country survey. Journal of Medical Economics, 2012, 15, 77-86.	2.1	75
10	Measuring the Impact of Diabetes Through Patient Report of Treatment Satisfaction, Productivity and Symptom Experience. Quality of Life Research, 2006, 15, 481-491.	3.1	74
11	Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study. Health and Quality of Life Outcomes, 2012, 10, 47.	2.4	71
12	Understanding and assessing the impact of treatment in diabetes: the Treatment-Related Impact Measures for Diabetes and Devices (TRIM-Diabetes and TRIM-Diabetes Device). Health and Quality of Life Outcomes, 2009, 7, 83.	2.4	62
13	Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Current Medical Research and Opinion, 2012, 28, 1933-1946.	1.9	60
14	Barriers to Initiating Insulin in Type 2 Diabetes Patients: Development of a New Patient Education Tool to Address Myths, Misconceptions and Clinical Realities. Patient, 2014, 7, 437-450.	2.7	60
15	Non-severe nocturnal hypoglycemic events: experience and impacts on patient functioning and well-being. Quality of Life Research, 2013, 22, 997-1004.	3.1	59
16	Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL). Quality of Life Research, 2007, 16, 1511-1520.	3.1	56
17	Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Current Medical Research and Opinion, 2012, 28, 1947-1958.	1.9	53
18	Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health and Quality of Life Outcomes, 2007, 5, 8.	2.4	49

#	Article	IF	Citations
19	Understanding the Economic Burden of Nonsevere Nocturnal Hypoglycemic Events: Impact on Work Productivity, Disease Management, and Resource Utilization. Value in Health, 2013, 16, 1140-1149.	0.3	47
20	The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. Journal of Medical Economics, 2014, 17, 751-761.	2.1	47
21	Understanding burden of illness for child growth hormone deficiency. Quality of Life Research, 2017, 26, 1673-1686.	3.1	37
22	Understanding Treatment Burden for Children Treated for Growth Hormone Deficiency. Patient, 2017, 10, 653-666.	2.7	34
23	Burden of Illness of Diabetic Peripheral Neuropathic Pain: A Qualitative Study. Patient, 2015, 8, 339-348.	2.7	30
24	The impact of non-severe hypoglycemic events on daytime function and diabetes management among adults with type 1 and type 2 diabetes. Journal of Medical Economics, 2012, 15, 869-877.	2.1	25
25	Understanding the burden of illness of excessive daytime sleepiness associated with obstructive sleep apnea: a qualitative study. Health and Quality of Life Outcomes, 2020, 18, 128.	2.4	25
26	Maximizing the value of validation findings to better understand treatment satisfaction issues for diabetes. Quality of Life Research, 2007, 16, 1053-1063.	3.1	24
27	Validation of the adult attention-deficit/hyperactivity disorder quality-of-life scale in European patients: comparison with patients from the USA. ADHD Attention Deficit and Hyperactivity Disorders, 2015, 7, 141-150.	1.7	23
28	The Economic Burden of Post-prandial Hyperglycemia (PPH) Among People with Type 1 and Type 2 Diabetes in Three Countries. Diabetes Therapy, 2016, 7, 75-90.	2.5	23
29	PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e372-e385.	3.6	23
30	Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures. Quality of Life Research, 2011, 20, 1513-8.	3.1	20
31	Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Research Notes, 2014, 7, 813.	1.4	20
32	Understanding Post-Prandial Hyperglycemia in Patients with Type 1 and Type 2 Diabetes: A Web-based Survey in Germany, the UK, and USA. Diabetes Therapy, 2016, 7, 335-348.	2.5	20
33	Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research and Opinion, 2017, 33, 639-645.	1.9	20
34	Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1357-1367.	3.6	20
35	Understanding the economic, daily functioning, and diabetes management burden of non-severe nocturnal hypoglycemic events in Canada: differences between type 1 and type 2. Journal of Medical Economics, 2014, 17, 11-20.	2.1	19
36	Assessing physical symptoms, daily functioning, and wellâ€being in children with achondroplasia. American Journal of Medical Genetics, Part A, 2021, 185, 33-45.	1.2	19

#	Article	IF	CITATIONS
37	Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom). Patient, 2020, 13, 151-162.	2.7	15
38	Functioning and wellâ€being in older children and adolescents with achondroplasia: A qualitative study. American Journal of Medical Genetics, Part A, 2022, 188, 454-462.	1.2	15
39	Diabetes management and daily functioning burden of nonâ€severe hypoglycemia in Japanese people treated with insulin. Journal of Diabetes Investigation, 2017, 8, 776-782.	2.4	14
40	Patient treatment satisfaction after switching to NovoMix® 30 (BIAsp 30) in the IMPROVEâ,, $^{\circ}$ study: an analysis of the influence of prior and current treatment factors. Quality of Life Research, 2010, 19, 1285-1293.	3.1	13
41	Insulin Administration and the Impacts of Forgetting a Dose. Patient, 2014, 7, 63-71.	2.7	13
42	Examining and interpreting responsiveness of the Diabetes Medication Satisfaction measure. Journal of Medical Economics, 2009, 12, 309-316.	2.1	12
43	Development and validation of the Treatment Related Impact Measure of Weight (TRIM-Weight). Health and Quality of Life Outcomes, 2010, 8, 19.	2.4	12
44	Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure. Quality of Life Research, 2015, 24, 3001-3014.	3.1	12
45	Cross-sectional 7-year follow-up of anxiety in primary care patients. Depression and Anxiety, 2004, 19, 105-111.	4.1	11
46	Validation of the controlled ovarian stimulation impact measure (COSI): assessing the patient perspective. Health and Quality of Life Outcomes, 2013, 11, 130.	2.4	11
47	Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom. Current Medical Research and Opinion, 2016, 32, 981-989.	1.9	10
48	Postprandial glucose and healthcare resource use: a cross-sectional survey of adults with diabetes treated with basal-bolus insulin. Journal of Medical Economics, 2018, 21, 66-73.	2.1	10
49	Assessing the impact of non-severe hypoglycemic events and treatment in adults: development of theÂTreatment-Related Impact Measureâ€"Non-severe Hypoglycemic Events (TRIM-HYPO). Quality of Life Research, 2015, 24, 2971-2984.	3.1	9
50	Assessing the Impact of Growth Hormone Deficiency and Treatment in Adults: Development of a New Disease-Specific Measure. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1204-1212.	3.6	8
51	A cross-sectional survey among patients and prescribers on insulin dosing irregularities and impact of mild (self-treated) hypoglycemia episodes in Spanish patients with type 2 diabetes as compared to other European patients. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion. 2014. 61. 426-433.	0.8	8
52	Assessing the impacts of having a child with achondroplasia on parent well-being. Quality of Life Research, 2021, 30, 203-215.	3.1	8
53	Living with hypoparathyroidism: development of the Hypoparathyroidism Patient Experience Scale-Impact (HPES-Impact). Quality of Life Research, 2021, 30, 277-291.	3.1	8
54	Validação semântica da versão em lÃngua portuguesa do Questionário de Qualidade de Vida em Adultos (AAQoL) que apresentam transtorno de déficit de atenção/hiperatividade (TDAH). Revista De Psiquiatria Clinica, 2011, 38, 87-90.	0.6	7

#	Article	IF	CITATIONS
55	Self-Treated Hypoglycemia in Type 2 Diabetes Mellitus: Results from the Second Wave of an International Cross-Sectional Survey. Diabetes Therapy, 2016, 7, 279-293.	2.5	6
56	Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM). PharmacoEconomics - Open, 2021, 5, 505-518.	1.8	6
57	Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD). PharmacoEconomics - Open, 2019, 3, 71-80.	1.8	5
58	What Is a Clinically Relevant Improvement in Quality of Life in Adults With ADHD?. Journal of Attention Disorders, 2019, 23, 65-75.	2.6	5
59	Psychometric validation of the Hypoparathyroidism Patient Experience Scales (HPES). Journal of Patient-Reported Outcomes, 2021, 5, 70.	1.9	5
60	A qualitative study of the impacts of having an infant or young child with achondroplasia on parent well-being. Orphanet Journal of Rare Diseases, 2021, 16, 351.	2.7	4
61	A cross-sectional survey among patients and prescribers on insulin dosing irregularities and impact of mild (self-treated) hypoglycemia episodes in Spanish patients with type 2 diabetes as compared to other European patients. EndocrinologÃa Y Nutrición (English Edition), 2014, 61, 426-433.	0.5	3
62	Perceptions of diabetes control among people with type 2 diabetes treated with basal insulin in Sweden, Switzerland, and the United Kingdom. Current Medical Research and Opinion, 2016, 32, 1653-1661.	1.9	3
63	Development of the Weight-Related Sign and Symptom Measure. Journal of Patient-Reported Outcomes, 2018, 2, 17.	1.9	3
64	<p>Divergence in perceptions of diabetes control among patients with type 2 diabetes mellitus treated with basal insulin and health care professionals: results from the US Perceptions of Control (POC-US) study</p> . Patient Preference and Adherence, 2019, Volume 13, 761-773.	1.8	3
65	Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom. Diabetes Therapy, 2019, 10, 1323-1336.	2.5	3
66	Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. Current Medical Research and Opinion, 2019, 35, 1623-1629.	1.9	3
67	Insulin-taking behavior and memory problems among people with diabetes in five countries: findings from a web survey. Patient Intelligence, 0, , 43.	0.2	2
68	Development and Validation of the Diabetes Pen Experience Measure (DPEM): A New Patient-Reported Outcome Measure. Journal of Diabetes Science and Technology, 2022, , 193229682210793.	2.2	O